Home Cart Sign in  
Chemical Structure| 301353-96-8 Chemical Structure| 301353-96-8

Structure of P7C3
CAS No.: 301353-96-8

Chemical Structure| 301353-96-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

P7C3 is a brain-penetrant NAMPT activator with proneurogenic and neuroprotective effect.

Synonyms: P7C3

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of P7C3

CAS No. :301353-96-8
Formula : C21H18Br2N2O
M.W : 474.19
SMILES Code : BrC1=CC2=C(N(C3=C2C=C(C=C3)Br)CC(CNC4=CC=CC=C4)O)C=C1
Synonyms :
P7C3
MDL No. :MFCD00572918
InChI Key :FZHHRERIIVOATI-UHFFFAOYSA-N
Pubchem ID :2836187

Safety of P7C3

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole with neuroprotective effects, which can be used for the research of neurodegenerative diseases, including Parkinson's disease[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 5.1 μM (GI50) 48 hours Assess cytotoxicity, GI50 of P7C3 was 5.1 μM PMC3033481
U2OS cells 10 nM 15 minutes P7C3 protects mitochondrial membrane potential PMC2930815
U2OS cells 5μM 72 hours Evaluate the protective effect of P7C3-A20 against doxorubicin-mediated toxicity, results showed P7C3-A20 significantly protected U2OS cells from doxorubicin toxicity PMC4163014
Mouse CD4+T cells 10 μM 3 days To investigate the effect of P7C3 on Th17 cell differentiation, results showed P7C3 significantly reduced the number of Th17-polarized CD4+T cells PMC8166969

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Ghsr-null mice and wild-type littermates Intraperitoneal injection 20 mg/kg/day Twice daily for 10 days P7C3 displayed antidepressant efficacy in the stressed, depression-prone Ghsr-null mice, reflected by reduced time spent in the corners of the testing chamber and increased time spent in the interaction zone. The more highly active analog P7C3-A20 exhibited antidepressant efficacy both in stressed Ghsr-null mice and in their more resilient, stressed wild-type littermates. PMC4206684
Mice Npas3-/- mice Oral 20 mg/kg Daily, until two months post-weaning P7C3 corrects morphological and electrophysiological deficits in the dentate gyrus of npas3-/- mice and enhances neurogenesis PMC2930815
Mice Alzheimer's disease model mice Intraperitoneal injection 20 mg/kg 4-5 days per week for 4-4.5 months P7C3 in combination with LV-Wnt3 promoted neural progenitor cell survival and increased adult hippocampal neurogenesis (AHN), but increasing AHN alone without elevated BDNF levels did not ameliorate cognition in 5×FAD mice. PMC6149542
Mice Neurodegenerative disease model Oral 5 mg kg/d Once daily for 7 days P7C3 increases the net magnitude of hippocampal neurogenesis by blocking apoptosis of neural precursor cells. PMC4237066
Mouse Type 2 diabetic db/db mice Intraperitoneal injection 10 mg/kg body weight Once daily for 4 weeks To evaluate the therapeutic effects of P7C3 in a type 2 diabetic mouse model, including improvements in insulin sensitivity, glycemic control, and skeletal muscle function PMC8977983

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.54mL

2.11mL

1.05mL

21.09mL

4.22mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories